ACM
SLN

Aquilo Capital Management’s Silence Therapeutics SLN Stock Holding History

Aquilo Capital Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-367,214
Closed -$2.53M – 15
2024
Q4 		$2.53M Buy
367,214
+50,000
+16% +$645K 3.81% 10
2024
Q3 		$5.77M Sell
317,214
-183,000
-37% -$3.4M 4.37% 8
2024
Q2 		$9.5M Sell
500,214
-74,000
-13% -$1.57M 9.16% 6
2024
Q1 		$12.4M Sell
574,214
-469,070
-45% -$10.2M 9.3% 6
2023
Q4 		$18.1M Sell
1,043,284
-268,949
-20% -$3.02M 11.29% 5
2023
Q3 		$12.9M Hold
1,312,233
– – 11.68% 4
2023
Q2 		$7.22M Hold
1,312,233
– – 4% 8
2023
Q1 		$8.14M Buy
1,312,233
+28,100
+2% +$331K 3.37% 11
2022
Q4 		$19.6M Buy
1,284,133
+21,008
+2% +$275K 7.36% 7
2022
Q3 		$12.7M Buy
+1,263,125
New +$13.3M 4.57% 9

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return

Aquilo Capital Management's SLN Position: Q1 2025 in Review

Aquilo Capital Management sold out of Silence Therapeutics (SLN) in Q1 2025, closing a stake of 367,214 shares — an estimated $2.53M sold.

Aquilo Capital Management first reported a position in SLN in Q3 2022 and held it in 10 quarters. The position peaked at $19.6M in Q4 2022. 59 funds tracked by Wall St. Rank hold SLN as of Q1 2025.

  • Aquilo Capital Management reported no remaining Silence Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Aquilo Capital Management sold 367,214 Silence Therapeutics shares in Q1 2025, an estimated $2.53M.
  • Aquilo Capital Management first reported a position in Silence Therapeutics in Q3 2022 and held it in 10 quarters.
  • Aquilo Capital Management's Silence Therapeutics position peaked at $19.6M in Q4 2022.
  • 59 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2025.

Based on Aquilo Capital Management's 13F filing for Q1 2025, filed 15 May 2025.